BioCentury
ARTICLE | Clinical News

Biosimilar insulin glargine: Phase III started

September 22, 2014 7:00 AM UTC

Mylan began the open-label U.S. Phase III INSTRIDE 1 trial to compare once-daily biosimilar insulin glargine vs. once-daily Lantus insulin glargine for 24 weeks in about 500 adult Type I diabetics re...